We next examined the effects of STAP-1 in cultures treated with JAK2 inhibitor, ruxolitinib, since JAK2-STAT5 pathway has been reported to be involved in development of CML LSC [19–21, 38]. This evidence concerns the gene JAK2 and chronic myelogenous leukemia, BCR-ABL1 positive.